<DOC>
	<DOCNO>NCT00276523</DOCNO>
	<brief_summary>RATIONALE : SCH 54031 ( PEG-interferon alfa-2b ) may interfere growth tumor cell slow growth head neck cancer . It may also stop growth head neck cancer block blood flow tumor . Giving PEG-interferon alfa-2b surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This randomized phase II trial study well different dos PEG-interferon alfa-2b work treat patient stage II , stage III , stage IV head neck cancer remove surgery .</brief_summary>
	<brief_title>PEG-interferon Alfa-2b Treating Patients With Stage II , Stage III , Stage IV Head Neck Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antiangiogenic effect PEG-interferon alfa-2b , term pre- post-treatment level microvessel density ( MVD ) , endothelial cell apoptosis , vascular endothelial growth factor ( VEGF ) , interleukin-8 , basic fibroblast growth factor ( bFGF ) , Nuclear Factor-KappaB ( NF-KB ) , matrix metalloproteinase/MMP-9 , NF-KB biopsy specimen , patient resectable stage II-IV squamous cell carcinoma head neck . Secondary - Determine toxicity profile drug patient . - Determine clinical response patient treated drug . OUTLINE : This randomize , control study . Patients randomize 1 4 treatment arm . - Arm I : Patients undergo surgery within 3 week randomization . - Arm II : Patients receive PEG-interferon alfa-2b subcutaneously day 1 , 8 , 15 . - Arm III : Patients receive PEG-interferon alfa-2b arm II high dose . - Arm IV : Patients receive PEG-interferon alfa-2b arm II high dose arm III . In arm II , III , IV , patient undergo surgery within 1 week completion PEG-interferon alfa-2b . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A maximum 72 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Stage II , III , IV disease One follow primary tumor site : Oral cavity Oropharynx Hypopharynx Larynx Resectable disease Scheduled undergo surgery primary treatment Distant metastases second primary tumor allow provided tumor deem resectable surgeon No squamous cell carcinoma nasopharynx skin PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 White Blood Cells ( WBC ) &gt; 3,000/mm^3 Platelet count ≥ 150,000/mm^3 Hemoglobin ≥ 10 g/dL Transfusion and/or epoetin alfa support allow provide give ≥ 1 week study entry AND patient stable Bilirubin &lt; 1.5 time upper limit normal ( ULN ) serum glutamic pyruvic transaminase ( SGPT ) ≤ 5 time ULN Creatinine &lt; 1.5 time ULN No hemolytic anemia No hemoglobinopathy ( e.g. , thalassemia ) No prior current ascites No bleeding varices No evidence decompensated liver disease No symptomatic ischemic heart disease No symptomatic congestive heart failure No uncontrolled heart condition No chronic obstructive pulmonary disease No document pulmonary hypertension No chronic pulmonary disease No known HIV positivity No AIDSrelated illness No active uncontrolled infection No immunologically mediate disease , include follow : Inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) Rheumatoid arthritis Idiopathic thrombocytopenia purpura Systemic lupus erythematosus Autoimmune hemolytic anemia Scleroderma Severe psoriasis No Central Nervous System ( CNS ) trauma No confusion disorientation No active seizure disorder require medication No spontaneous encephalopathy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexisting uncontrolled thyroid abnormality No poorly control diabetes mellitus No history major psychiatric illness would prelude give informed consent No nonmalignant systemic disease would preclude study participation PRIOR CONCURRENT THERAPY : More 4 week since prior biologic therapy recover More 4 week since prior chemotherapy recover More 4 week since prior radiotherapy recover More 4 week since prior surgery No prior interferon No concurrent immunotherapy No concurrent chemotherapy No concurrent hormonal antineoplastic therapy No concurrent systemic corticosteroid No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
</DOC>